Physician profile
Frank Mark Basich
NPI 1811902257
$3,470.37
in general payments reported to CMS, 2019-2025
14 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $487 · 2021: $300 · 2022: $186 · 2023: $1,057 · 2024: $442 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,742.95 | 2019-2025 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Idose |
| Alcon Vision LLC | $854.69 | 2019-2025 | Ngenuity, Lensx, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $194.50 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $144.79 | 2024-2025 | Xdemvy |
| Ivantis, INC | $142.63 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.81 | 2019-2021 | |
| Biotissue Holdings INC. | $98.14 | 2025 | |
| Dompe US, INC. | $40.87 | 2019 | |
| Optos, INC. | $35.27 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $24.30 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.01 | 2022 | |
| Sight Sciences, INC. | $20.99 | 2022 | |
| Iridex Corporation | $18.71 | 2021 | |
| Kala Pharmaceuticals, INC. | $17.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Basich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.